OMEX, Odyssey Marine Exploration Incorporated

** OMEX has confirmed the identity and location of the SS Gairsoppa, the Largest Known Silver Shipwreck Cargo site, and OMEX may retain 80% of the net salved value of the silver bullion.

OMEX is engaged in deep-ocean exploration using innovative methods and state-of-the-art technology. OMEX is a world leader in shipwreck exploration, conducting extensive search and archaeological recovery operations on deep-ocean shipwrecks around the world.

More about OMEX at www.shipwreck.net

****

GNRC, Generac Holdings Incorporated

Recent wide-scale power outages in the Midwest and East Coast is directly impacting sales of portable generator shipments.

** GNRC has updated its business outlook for the second half of fiscal 2011. As a result of recent events, GNRC now expects that residential product sales in the third quarter of 2011 will increase year-over-year by over 50% driven primarily by portable generator shipments residential product sales in the fourth quarter of 2011 will increase year-over-year by approximately 15-20% as a result of increased shipments of home standby generators, with demand for these products expected to remain strong into fiscal 2012 in the regions impacted by major outages.

GNRC is a leading designer and manufacturer of a wide range of backup power generation products serving residential, light commercial and industrial markets.

More about GNRC at www.generac.com

****

MELA, MELA Sciences Incorporated

** MELA reported that the FDA has issued an Approvable Letter for the MelaFind Pre-Market Approval application.

MELA's MelaFind is intended for use on clinically atypical cutaneous pigmented lesions with one or more clinical or historical characteristics of melanoma, excluding those with a clinical diagnosis of melanoma or likely melanoma.

MELA is a medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations. MELA's flagship product, MelaFind®, is intended to be used when a trained dermatologist chooses to obtain additional information to help decide whether to biopsy certain indeterminate pigmented skin lesions.

More about MELA at www.melasciences.com

CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.

Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.